2011
DOI: 10.1177/009286151104500515
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Objective: Assess the newspaper coverage of off-label drug use from the years 1990 to 2010.Methods: News articles from the top six selling national newspapers were studied. Variables of interest were the number of articles published, article themes, headline and content tone, concerns and benefits discussed with offlabel use, drugs discussed, and primary individuals interviewed for the article.Results: The number of articles published on off-label drug and device use steadily increased over the period of the s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

2
0
0

Year Published

2013
2013
2013
2013

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 25 publications
2
0
0
Order By: Relevance
“…Excluded articles included articles not on breast cancer (42%), financial reports (31%), articles not pertaining to bevacizumab (8%), articles where the full text was not available (7%), letters to the editor (7%), and neoadjuvant articles (5%). The percentage of articles excluded is consistent with previous content analysis studies using newspaper databases [17,20,21]. Of the articles, 22% were from the pre-approval time period, 62% were from the approval period, and 16% were from the loss of approval time period.…”
Section: General Characteristicssupporting
confidence: 85%
“…Excluded articles included articles not on breast cancer (42%), financial reports (31%), articles not pertaining to bevacizumab (8%), articles where the full text was not available (7%), letters to the editor (7%), and neoadjuvant articles (5%). The percentage of articles excluded is consistent with previous content analysis studies using newspaper databases [17,20,21]. Of the articles, 22% were from the pre-approval time period, 62% were from the approval period, and 16% were from the loss of approval time period.…”
Section: General Characteristicssupporting
confidence: 85%
“…Excluded articles included articles not on breast cancer (42%), financial reports (31%), articles not pertaining to bevacizumab (8%), articles where the full text was not available (7%), letters to the editor (7%), and neoadjuvant articles (5%). The percentage of articles excluded is consistent with previous content analysis studies using newspaper data-bases [17,20,21]. Of the articles, 22% were from the pre-approval time period, 62% were from the approval period, and 16% were from the loss of approval time period.…”
Section: General Characteristicssupporting
confidence: 85%